Myasthenia Gravis

Overview

Myasthenia gravis (MG) is a chronic autoimmune disease in which antibodies disrupt signaling between nerves and voluntary muscles at the neuromuscular junction. This produces fluctuating weakness that commonly affects the eye, facial, swallowing, speech, neck, breathing, and limb muscles; weakness typically worsens with activity and improves with rest. MG can occur at any age, and severe exacerbations can impair breathing or swallowing. Myasthenia Gravis

With modern treatment, many people achieve good symptom control and normal or near-normal daily lives, although some have persistent or treatment-resistant disease. Standard care combines symptom relief with pyridostigmine, immune suppression such as corticosteroids and steroid-sparing medicines, rapid rescue treatments such as intravenous immunoglobulin or plasma exchange when needed, and thymectomy for selected patients. Newer antibody-targeting medicines—including complement inhibitors and neonatal Fc receptor (FcRn) blockers that lower circulating disease-causing immunoglobulin G (IgG)—have expanded options, but they generally require repeated treatment and are not cures. International Consensus Guidance Myasthenia Gravis

Scope of Recent Research (2020–present)

Research activity has accelerated substantially since 2020, especially around selectively removing pathogenic antibodies, depleting the B cells or plasma cells that make them, and rebuilding a more tolerant immune system. The field has produced several effective symptom-controlling medicines and early evidence that cell therapies or intensive immune-reset approaches might induce prolonged treatment-free remission in a subset of people with severe MG; however, no therapy has yet been proven to cure MG reliably and safely across its diverse antibody-defined forms. BCMA-directed mRNA CAR-T trial Refractory MG treated with HSCT

Major Breakthroughs and Emerging Therapies

A major near-term advance has been antibody lowering rather than immune eradication. FcRn blockers prevent the body from recycling IgG, reducing both total IgG and harmful MG autoantibodies. Efgartigimod became the first approved drug in this class for acetylcholine-receptor-antibody-positive generalized MG in 2021, and nipocalimab was approved in the United States in April 2025 for antibody-positive generalized MG in people aged 12 years and older. These drugs can improve daily function and weakness but need ongoing dosing, so they are disease control rather than curative treatment. FDA approval of efgartigimod FDA review of nipocalimab

The most consequential cure-oriented clinical strategy is engineered cell therapy directed against B-cell maturation antigen (BCMA), a target expressed by antibody-producing plasmablasts and plasma cells. Descartes-08 uses a patient’s own T cells, temporarily programmed with messenger RNA to express a BCMA-targeting chimeric antigen receptor (CAR). In a randomized phase 2b trial of 26 people with generalized MG, 10 of 15 treated participants versus 3 of 11 placebo participants achieved the primary month-three improvement threshold; the investigators reported sustained clinically meaningful responses through month 12 in 83% of treated participants. One third reached minimal symptom expression by month six, but this does not yet establish permanent immune tolerance or cure. BCMA-directed mRNA CAR-T trial

Other CAR-T approaches seek a deeper immune reset. A 2024 report described two people with highly refractory acetylcholine-receptor- or MuSK-antibody-positive MG who received BCMA CAR-T cells and had persistent clinical improvement through 18 months, accompanied by reconstitution of B-cell populations and lower pathogenic autoantibodies. This is encouraging mechanistic evidence, but it is a two-patient report rather than definitive proof of efficacy or long-term safety. BCMA CAR-T immune reconstitution study

A more precise preclinical approach is chimeric autoantibody receptor T-cell therapy, or CAAR-T. Instead of deleting broad groups of antibody-producing cells, researchers at the University of Pennsylvania and Yale engineered T cells carrying a piece of the acetylcholine receptor so that they recognize and kill B cells making anti-acetylcholine-receptor antibodies. In a mouse xenograft model, an optimized CAAR-T design eliminated target B cells and maintained cell-surface receptor expression, providing a foundation for antigen-specific treatment that could spare much of normal immunity; it has not yet been tested in people with MG. AChR CAAR-T preclinical study

Autologous hematopoietic stem-cell transplantation (HSCT) is another immune-reset strategy. It uses high-intensity chemotherapy and immune-cell depletion to remove much of the existing autoreactive immune system, followed by reinfusion of a patient’s blood-forming stem cells. In a 2025 retrospective series of 21 severely refractory patients, 16 of 18 evaluable patients reached stable remission or minimal manifestations without treatment, but the 100-day transplant-related mortality was 9.5%. HSCT therefore offers important proof that durable treatment-free remission can be possible, while also showing why this intensive approach is not currently appropriate for routine MG care. Refractory MG treated with HSCT

Clinical Trials and Experimental Approaches

Cartesian Therapeutics’ Descartes-08 study, NCT04146051, progressed from a phase 1b/2a outpatient study without lymphodepleting chemotherapy to a randomized phase 2b trial. The earlier study enrolled 14 participants and reported no dose-limiting toxicity, cytokine-release syndrome, or neurotoxicity, alongside clinically meaningful improvements in MG severity measures; the later placebo-controlled phase 2b results provide the strongest controlled evidence so far for a cell therapy in MG. The ClinicalTrials.gov record lists Cartesian as sponsor and describes the study as phase 2 and active but not recruiting in its May 2025 update. Descartes-08 phase 1b/2a study Descartes-08 trial record BCMA-directed mRNA CAR-T trial

Additional BCMA CAR-T programs are entering earlier-stage testing. CSPC ZhongQi Pharmaceutical Technology’s SYS6020 trial, NCT06688435, is a recruiting, open-label phase 1 dose-escalation and dose-expansion study in refractory generalized MG, with an estimated enrollment of 50 and no posted clinical outcomes. These studies will be important for determining whether more durable plasma-cell depletion can be delivered with acceptable risks outside highly specialized settings. SYS6020 trial record

Conventional drug trials continue to improve disease control while curative research develops. Janssen’s phase 3 Vivacity-MG3 trial of nipocalimab enrolled adults with generalized MG on standard treatment; FDA’s review reported a placebo-adjusted improvement of 1.5 points in the MG Activities of Daily Living score at weeks 22–24, supporting the April 2025 approval. This illustrates the current distinction between validated disease management and experimental immune-reset therapy. Nipocalimab FDA trial snapshot

Methodologies and Scientific Approaches

MG researchers use antibody subtype, circulating autoantibody concentration, immunoglobulin levels, B-cell and plasma-cell subsets, and standardized clinical measures such as MG Activities of Daily Living, Quantitative MG, and MG Composite scores to connect biological changes with real-world muscle function. The Descartes-08 program also uses transient messenger-RNA CAR expression, repeated outpatient infusions, and no lymphodepleting chemotherapy in an effort to reduce the severe inflammatory and neurologic toxicities associated with conventional DNA-based CAR-T therapy. Descartes-08 phase 1b/2a study BCMA-directed mRNA CAR-T trial

Mechanistic work spans engineered human-cell systems, mouse xenografts, serial blood sampling, flow cytometry, autoantibody assays, single-cell RNA sequencing, and T-cell-receptor sequencing. These methods are being used to identify which immune-cell states predict benefit, whether pathogenic antibodies remain suppressed after treatment, and whether a rebuilt B-cell compartment is less likely to recreate autoimmunity. BCMA CAR-T immune reconstitution study AChR CAAR-T preclinical study

Leading Institutions and Funding

Key contributors include Cartesian Therapeutics and a multicenter North American MG trial network for Descartes-08; Tongji Hospital and Huazhong University of Science and Technology, with collaborators in Germany and industry partners, for conventional BCMA CAR-T research; the University of Pennsylvania and Yale School of Medicine for antigen-specific AChR CAAR-T development; and the University of Calgary and The Ottawa Hospital for HSCT research. The initial Descartes-08 phase 1b/2a study reported support from Cartesian Therapeutics and the National Institute of Neurological Disorders and Stroke. Descartes-08 phase 1b/2a study BCMA CAR-T immune reconstitution study AChR CAAR-T preclinical study Refractory MG treated with HSCT

Patient-led funding remains important for a relatively uncommon disease. The Myasthenia Gravis Foundation of America’s current programs include High Impact Pilot Project awards of up to $110,000 over two years, a Clinician Scientist Development Award totaling $240,000 over three years, and a Nancy Law Impact Award that received $300,000 over three years in the 2024 grant cycle. MGFA grant funding programs

Strengths, Limitations, and Challenges

The central strength of current cure-oriented work is that it targets the cause of antibody-mediated MG more directly than conventional broad immunosuppression. BCMA-directed therapies aim at long-lived antibody-producing cells, while AChR CAAR-T could, in principle, delete only the B cells responsible for a particular autoantibody. HSCT and CAR-T reports also demonstrate that prolonged treatment-free remission is biologically plausible. BCMA-directed mRNA CAR-T trial AChR CAAR-T preclinical study Refractory MG treated with HSCT

The limitations are substantial. The best randomized CAR-T evidence remains small, with 15 treated participants, and its longest reported controlled follow-up is 12 months. Cell therapy can cause infusion reactions and may create infection, blood-count, manufacturing, and access challenges; HSCT carries a particularly serious treatment-related mortality risk. MG is also biologically heterogeneous: acetylcholine-receptor, MuSK, and seronegative disease may not respond equally to a single cell target, and improvement on clinical scales is not the same as verified, permanent elimination of autoimmune disease. BCMA-directed mRNA CAR-T trial Refractory MG treated with HSCT Nipocalimab FDA trial snapshot

Outlook and Future Directions

MG is not close to having a broadly available cure, but it is closer than it was in 2020 to demonstrating durable, treatment-free immune remission in carefully selected patients. The pivotal milestones will be larger controlled trials of BCMA-directed CAR-T therapies with multi-year follow-up, confirmation that autoantibodies and disease activity stay suppressed after immune reconstitution, safer and scalable manufacturing, and first-in-human testing of antigen-specific strategies such as AChR CAAR-T. Until those milestones are met, FcRn blockers, complement-directed drugs, thymectomy where appropriate, and conventional immunotherapy remain essential treatments rather than substitutes for a cure. BCMA-directed mRNA CAR-T trial AChR CAAR-T preclinical study International Consensus Guidance

References

• Myasthenia Gravis — National Institute of Neurological Disorders and Stroke, 2025.
• International Consensus Guidance — Narayanaswami et al., 2021.
• FDA approval of efgartigimod — U.S. Food and Drug Administration, 2021.
• FDA review of nipocalimab — U.S. Food and Drug Administration, 2025.
• BCMA-directed mRNA CAR-T trial — Vu et al., 2026.
• Descartes-08 phase 1b/2a study — Vu et al., 2023.
• Descartes-08 trial record — ClinicalTrials.gov, 2025.
• BCMA CAR-T immune reconstitution study — Tian et al., 2024.
• AChR CAAR-T preclinical study — Oh et al., 2025.
• Refractory MG treated with HSCT — Beland et al., 2025.
• SYS6020 trial record — ClinicalTrials.gov, 2025.
• MGFA grant funding programs — Myasthenia Gravis Foundation of America, 2026.